According to The Insight Partners’ Latest Study on “Liposome Drug Delivery Market Forecast to 2027″ Focuses COVID-19 Impact and Global Analysis by Product (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, Others); Technology ( Stealth Liposome Technology, Non-PEGylated Liposome Technology, DepoFoam Liposome Technology, Lysolipid Thermally Sensitive Liposome (LTSL)); Application (Fungal Diseases, Cancer Therapy, Pain Management, Viral Vaccines, Photodynamic Therapy)
“Liposome Drug Delivery Market is expected to reach US$ 6,992.95 million by 2027 from US$ 3,594.41 million in 2019. The report highlights trends prevailing in the global liposome drug delivery market and the factors driving market along with those that act as hindrances.
Download PDF Sample Copy at:
https://www.theinsightpartners.com/sample/TIPRE00010407/
Liposomes contain an aqueous solution core that is surrounded by a hydrophobic membrane as a lipid bilayer. The liposomes work by delivering the drug by diffusion than that of direct cell fusion. These biomolecules are emerging in drug delivery systems as they improve therapeutic index of the established as well as new drugs by modifying the drug absorption, reducing the metabolism and prolonging their biological half-life through reduced toxicity.
Market Leaders Analysis:
Market leaders operating in the market have undertaken various inorganic and organic growth strategies in the liposome drug delivery market. The liposome drug delivery market majorly consists of the players such as Takeda Pharmaceutical Company Limited, Novartis AG, Luye Pharma Group, Ipsen Pharma, CELSION, Inc., Gilead Sciences, Inc., Astellas Pharma, Inc., Johnson & Johnson Services, Inc., Pacira Biosciences, Inc. and Acrotech Biopharma, Inc. Inorganic growth strategies witnessed in the market such as partnerships, collaboration, and mergers & acquisitions have paved way for expansion of business and customer base of market players
Below is the list of the growth strategies done by the players operating in the liposome drug delivery market:
April, 2019: Luye Pharma’s Lipusu, an innovative paclitaxel liposome formulation was included and approved as a first-line drug for non-squamous cell carcinoma in the Chinese Society of Clinical Oncology (CSCO) Guidelines
April, 2019: Ipsen Pharma completed acquisition of global oncology assets from Merrimack Pharmaceuticals, in Cambridge that focuses on ONIVYDE (irinotecan liposome injection) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy
Have a Call with Analyst:
https://www.theinsightpartners.com/speak-to-analyst/TIPRE00010407/
March, 2019: Acrotech Biopharma L.L.C., a step-down subsidiary of Aurobindo Pharma Limited, India completed acquisition of seven FDA-approved hematology/oncology products Spectrum Pharmaceuticals, Inc. One of the seven products include MARQIBO (vinCRIStine sulfate LIPOSOME injection)
Regional Overview:
North America held the largest share of the liposome drug delivery market. The burgeoning penetration of nanotechnology in drug delivery systems translated into commercially viable products is likely to be responsible for the dominance of the market. Furthermore, the presence of key market leaders in the region investing huge amounts in R&D of new drug delivery channels to improve the efficacy of drugs are expected to come up with novel liposomal solutions in the near future securing potential growth in the market. On the other hand, Asia Pacific is currently a niche market and has high potential for growth, which is attributed to the increasing number of patients with chronic diseases and growing R&D spending by pharmaceutical giants in the region, thereby opening opportunities for developing robust pipeline for liposomal drugs. In addition, the rising disposable incomes among Asian population leading to increasing awareness toward healthy lifestyle is likely to propel the market growth.
The liposome drug delivery market, by application, is segmented into fungal diseases, cancer therapy, pain management, viral vaccines, and photodynamic therapy. In 2019, the cancer therapy segment accounted for the largest market share of the global liposome drug delivery market. The liposome-based treatments have gained popularity to overcome the problems and side effects of the conventional chemotherapy treatment. Liposomal drugs have high encapsulation capacity and hence show a significant anticancer activity with decreased toxicity. Furthermore, drug delivery systems enhance the therapeutic index of anticancer agents and these biomolecules have a natural ability to target cancer cells. The aforementioned factors are likely to be responsible for the growth of the segment in the liposome drug delivery market.
Buy Report at:
https://www.theinsightpartners.com/buy/TIPRE00010407/
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876